NCT02824068View on ClinicalTrials.gov

Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study)

CompletedOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2020

Conditions
Pompe Disease
Interventions
DRUG

glucosidase alfa

Long-term use in an observational study of licenced drug

Trial Locations (3)

80336

Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany, Munich

98125

5. Department of Clinical and Experimental Medicine, Reference Center for Rare Neuromuscular Disorders, University of Messina, Italy, Messina

Unknown

National Taiwan University Hospital Taipei, Taipei

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

LMU Klinikum

OTHER

NCT02824068 - Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study) | Biotech Hunter | Biotech Hunter